期刊文献+

紫星口服液治疗晚期肺癌的临床观察 被引量:10

Clinical Trial on the Effects of Shikonin Mixture on Later Stage Lung Cancer
原文传递
导出
摘要 本组报告了单纯服用紫星口服液治疗19例晚期肺癌患者,其近期临床疗效观察证明紫星口服液可明显抑制肺癌的发展,提高机体的免疫功能。瘤块缩小25%以上客观有效率63.3%,总缓解率36.9%,治疗后一年生存率为47.3%,中位生存期在10个月左右,其中腺癌为10个月,鳞癌为12个月。为延长患者生存期,提高生存质量开辟了一条有效的治疗方法。 The Shikonin mixture was used for 19 cases of later-stage lung cancer who were not the candidates for operation,radiotherapy and chemotherapy.The clinical observation showed that Shikonin mixture could inhibit the growth of lung cancer and improve the immune function of the body.The tumors were reduced over 25% in diameter.The effective rate was 63.3%,remission rate 36.9%,survival rate of one year 47.3%.The intermedium survival period was about 10 months, including adenocarcinoma 10 months,squamous carcinoma 12 months. After treatment the life quality of patients were greatly improved.The patients got better appetite and their body weights were increased.They could manage themselves in daily life.The Karnofsky scores were enhanced by 20.The authors also observed that Shikonin mixture could relieve such symptoms as cough, bloody sputum and chest pain caused by lung cancer.The levels of cells and interleukin-2 were increased(P<0.001).It had no harmful effects on peripheral blood picture,heart,kidney and liver.Shikonin mixture is safe and effective for later-stage cance.
出处 《中西医结合杂志》 CSCD 北大核心 1991年第10期598-599,共2页
关键词 紫星口服液 肺肿瘤 NK细胞 Shikonin mixture lung cancer NK cell Interleukin-2
  • 引文网络
  • 相关文献

同被引文献118

引证文献10

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部